{"id":"ritonavir-norvir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"10-15","effect":"Taste perversion"},{"rate":"2-5","effect":"Hepatotoxicity"},{"rate":"15-25","effect":"Lipid abnormalities (elevated triglycerides and cholesterol)"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"variable","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ritonavir is a protease inhibitor that binds to HIV protease and prevents the enzyme from cleaving viral precursor proteins into their functional forms. This results in the production of immature, non-infectious viral particles. Ritonavir is also commonly used as a pharmacokinetic booster in combination antiretroviral regimens, where it inhibits cytochrome P450 metabolism to increase the plasma concentrations of other protease inhibitors.","oneSentence":"Ritonavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:21.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination with other antiretroviral agents)"},{"name":"Used as a pharmacokinetic booster for other protease inhibitors"}]},"trialDetails":[{"nctId":"NCT05965726","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID-19, Long COVID","enrollment":964},{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT03907046","phase":"PHASE3","title":"Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","status":"RECRUITING","sponsor":"Yale University","startDate":"2020-01-28","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation","enrollment":700},{"nctId":"NCT05334004","phase":"PHASE1","title":"Lopinavir/Ritonavir in PLWH With High-Grade AIN","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-12-19","conditions":"High-Grade Anal Intraepithelial Neoplasia","enrollment":21},{"nctId":"NCT06160128","phase":"","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-09-26","conditions":"COVID-19, SARS-CoV-2 Infection, RSV, Influenza","enrollment":400000},{"nctId":"NCT07072793","phase":"","title":"A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-10-31","conditions":"COVID-19 (Coronavirus Disease 2019)","enrollment":131005},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT07157007","phase":"PHASE2","title":"Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","status":"RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-09-16","conditions":"COVID - 19","enrollment":90},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT06397144","phase":"PHASE1","title":"A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-08-15","conditions":"Biological Availability, Healthy Participants","enrollment":""},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT07261085","phase":"","title":"A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-27","conditions":"COVID-19","enrollment":99000},{"nctId":"NCT05595369","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID, Long Covid19","enrollment":963},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06085924","phase":"","title":"A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-07","conditions":"COVID-19","enrollment":8252912},{"nctId":"NCT05852873","phase":"PHASE3","title":"PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2023-05-12","conditions":"Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19","enrollment":2000},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT07002242","phase":"PHASE1","title":"A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2022-07-06","conditions":"Healthy","enrollment":15},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT06683937","phase":"","title":"Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-01","conditions":"Immunocompromised Patients, SARS-CoV-2 Disease","enrollment":300},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT05576662","phase":"PHASE2","title":"Paxlovid for Treatment of Long Covid","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-11-08","conditions":"Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID","enrollment":168},{"nctId":"NCT05263908","phase":"","title":"A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-31","conditions":"SARS-CoV-2 Infection","enrollment":3346},{"nctId":"NCT06291831","phase":"","title":"A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-13","conditions":"COVID-19","enrollment":3011},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT06799650","phase":"PHASE2","title":"Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV","status":"RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-01-01","conditions":"HIV Seropositivity","enrollment":40},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT07090486","phase":"","title":"A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-15","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05386472","phase":"PHASE1","title":"A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-06-22","conditions":"COVID-19","enrollment":25},{"nctId":"NCT07089680","phase":"","title":"A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-18","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1200},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT05261139","phase":"PHASE3","title":"EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-03-07","conditions":"COVID-19","enrollment":160},{"nctId":"NCT01935674","phase":"PHASE4","title":"Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2013-09","conditions":"HIV, Hypercholesterolaemia","enrollment":43},{"nctId":"NCT04960202","phase":"PHASE2, PHASE3","title":"EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-16","conditions":"COVID-19","enrollment":2091},{"nctId":"NCT01602822","phase":"PHASE4","title":"Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV","status":"TERMINATED","sponsor":"Kenneth H. Mayer, MD","startDate":"2012-02","conditions":"HIV","enrollment":11},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT06428045","phase":"PHASE1","title":"STARLITE for Unresectable High-Grade Gliomas","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-04-15","conditions":"High Grade Glioma","enrollment":24},{"nctId":"NCT05263895","phase":"PHASE1","title":"Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-03","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT06016556","phase":"","title":"A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-17","conditions":"Covid-19","enrollment":250},{"nctId":"NCT05614349","phase":"PHASE3","title":"Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings","status":"ACTIVE_NOT_RECRUITING","sponsor":"Unity Health Toronto","startDate":"2023-01-16","conditions":"COVID-19","enrollment":797},{"nctId":"NCT03593954","phase":"PHASE1","title":"A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-31","conditions":"Healthy","enrollment":12},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT06710990","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-02-17","conditions":"Advanced Breast Cancer","enrollment":32},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT06792214","phase":"PHASE4","title":"Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-01-03","conditions":"SARS CoV-2 Post-Acute Sequelae","enrollment":118},{"nctId":"NCT02249442","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-10-01","conditions":"Hepatic Insufficiency","enrollment":24},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT06735300","phase":"","title":"Saliva PCR in Pregnant Women with COVID-19","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-06-01","conditions":"Coronavirus Disease 2019 (COVID-19) Pneumonia","enrollment":37},{"nctId":"NCT05850728","phase":"PHASE1","title":"First in Human Study of TLC-ART 101 (ACTU 2001)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2023-04-01","conditions":"Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy","enrollment":12},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT05823896","phase":"PHASE2","title":"ImPROving Quality of LIFe in the Long COVID Patient","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2023-05-01","conditions":"Post-COVID-19 Syndrome, Long COVID, Long Covid19","enrollment":219},{"nctId":"NCT05668091","phase":"PHASE2","title":"A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.","status":"COMPLETED","sponsor":"Harlan M Krumholz","startDate":"2023-04-14","conditions":"Long COVID","enrollment":100},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT05718518","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2023-01-13","conditions":"Healthy, COVID-19","enrollment":72},{"nctId":"NCT06676410","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants","status":"RECRUITING","sponsor":"Code Pharma","startDate":"2023-07-20","conditions":"HIV, HIV Infection","enrollment":40},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05898672","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-09","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":12},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT05339334","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT05567952","phase":"PHASE2","title":"A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-19","conditions":"COVID-19","enrollment":436},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT06610643","phase":"NA","title":"Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-21","conditions":"COVID-19, SARS-CoV-2, Immunocompromised","enrollment":40},{"nctId":"NCT05487040","phase":"PHASE1","title":"A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-07","conditions":"COVID-19","enrollment":15},{"nctId":"NCT05438602","phase":"PHASE2","title":"A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-03","conditions":"COVID-19","enrollment":158},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT02735863","phase":"PHASE2","title":"ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2016-05","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT05525910","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Biological Availability, Healthy Participants","enrollment":15},{"nctId":"NCT05679388","phase":"PHASE1","title":"A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-02-13","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT04390152","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19","status":"TERMINATED","sponsor":"BioXcellerator","startDate":"2020-01-13","conditions":"Acute Respiratory Distress Syndrome","enrollment":6},{"nctId":"NCT02460133","phase":"PHASE4","title":"Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2015-07-10","conditions":"Hepatitis C Virus","enrollment":44},{"nctId":"NCT04268472","phase":"NA","title":"Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg (\"Jonson&Jonson\", Russia)","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-06-06","conditions":"Bioequivalence","enrollment":44},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04147208","phase":"PHASE2","title":"Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2019-02-28","conditions":"Chronic HBV Infection","enrollment":250},{"nctId":"NCT06205329","phase":"PHASE1","title":"Study of WPV01 in Healthy Subjects","status":"COMPLETED","sponsor":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","startDate":"2022-10-03","conditions":"Healthy Participants","enrollment":108},{"nctId":"NCT05263921","phase":"PHASE1","title":"Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT03066154","phase":"PHASE1","title":"Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2016-09","conditions":"Prostatic Neoplasms","enrollment":24},{"nctId":"NCT05953545","phase":"PHASE2","title":"Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-05-22","conditions":"Chronic Hepatitis Delta","enrollment":""},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":2,"reaction":"MATERNAL DRUGS AFFECTING FOETUS"},{"count":2,"reaction":"VENTRICULAR SEPTAL DEFECT"},{"count":1,"reaction":"ACCESSORY AURICLE"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"CONGENITAL FOOT MALFORMATION"},{"count":1,"reaction":"CRYPTORCHISM"},{"count":1,"reaction":"DRUG-INDUCED LIVER INJURY"}],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ritonavir (Norvir)","genericName":"Ritonavir (Norvir)","companyName":"Germans Trias i Pujol Hospital","companyId":"germans-trias-i-pujol-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ritonavir, also known as Norvir, is a small molecule used to boost the levels of other antiviral medications. It is primarily used to treat HIV infections, although it has also been studied in clinical trials for other conditions such as COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}